Biohaven Achieves Significant Milestones in First Quarter 2025 Amidst Economic Challenges Biohaven Ltd. reports promising financial results for Q1 2025, highlighting significant funding agreements and ongoing clinical developments amid economic uncertainties.

Biohaven Achieves Significant Milestones in First Quarter 2025 Amidst Economic Challenges #United_States #Biohaven #New_Haven #Troriluzole #Oberland_Capital

Biohaven Secures Major Investment from Oberland Capital to Enhance Development of Troriluzole for Rare Diseases Biohaven Ltd. has announced a substantial investment of up to $600 million from Oberland Capital, aimed at furthering the development of their innovative therapy, Troriluzole, targeting rare genetic diseases.

Biohaven Secures Major Investment from Oberland Capital to Enhance Development of Troriluzole for Rare Diseases #United_States #Biohaven #New_Haven #BHVN #Oberland_Capital